Literature DB >> 20924879

Advanced urine toxicology testing.

Peter L Tenore1.   

Abstract

Urine toxicology screening testing is an important standard of care in the addiction and pain treatment setting, offering a reproducible, unbiased, and accurate laboratory test to monitor patients and provide objective support for clinical observations. It has been shown that physicians do not have proficiency in the ordering or interpretation of these tests. This article is an attempt to respond to that need. Current antibody-based enzymatic immunoassays (EIAs) used for urine toxicology screening are useful to detect classes of drugs (ex., opiate) but cannot determine which specific drug (ex., morphine) is present. Gas chromatography and mass spectroscopy can determine exactly which drugs are present, allowing prescribed (or illicit) opiates and benzodiazepines to be identified. This article will discuss principles and details of opiate and benzodiazepine EIA and gas chromatography and mass spectroscopy urine toxicology testing. The approach to detecting patients attributing positive opiate EIAs to prescription opiates who are using heroin or other opioids will be reviewed. Cases of controlled prescription drugs that do not produce the expected positive urine tests (ex., oxycodone producing negative opiate screening tests) will be discussed. How to differentiate codeine from heroin and the role of poppy seeds in toxicology will be examined. The case of an anti-depressant drug that produces false-positive benzodiazepine results and antibiotics that cause positive opiate urine toxicology results will be reviewed. Common benzodiazepines (ex., clonazepam and lorazepam) that do not reliably produce positive benzodiazepine EIAs will be discussed. The approach to detection and management of all these types of toxicology cases will be reviewed, and it is hoped that the analyses presented will impart an adequate information base to medical providers and staff members of drug treatment and pain centers, enabling them to order and interpret these tests in the clinic more effectively as an integrated part of whole patient care.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20924879     DOI: 10.1080/10550887.2010.509277

Source DB:  PubMed          Journal:  J Addict Dis        ISSN: 1055-0887


  16 in total

1.  Toxicologic testing for opiates: understanding false-positive and false-negative test results.

Authors:  Christopher J Keary; Ying Wang; Jonathan R Moran; Lazaro V Zayas; Theodore A Stern
Journal:  Prim Care Companion CNS Disord       Date:  2012-07-26

2.  They don't know what they don't know: internal medicine residents' knowledge and confidence in urine drug test interpretation for patients with chronic pain.

Authors:  Joanna L Starrels; Aaron D Fox; Hillary V Kunins; Chinazo O Cunningham
Journal:  J Gen Intern Med       Date:  2012-07-20       Impact factor: 5.128

3.  Urgent monitoring of direct oral anticoagulants in patients with atrial fibrillation: a tentative approach based on routine laboratory tests.

Authors:  Giuseppe Lippi; Diego Ardissino; Roberto Quintavalla; Gianfranco Cervellin
Journal:  J Thromb Thrombolysis       Date:  2014       Impact factor: 2.300

4.  Comparison of Response of DRI Oxycodone Semiquantitative Immunoassay With True Oxycodone Values Determined by Liquid Chromatography Combined With Tandem Mass Spectrometry: Sensitivity of the DRI Assay at 100 ng/ml Cut-Off and Validity of Semiquantitative Value.

Authors:  R Brent Dixon; Bonnette Davis; Amitava Dasgupta
Journal:  J Clin Lab Anal       Date:  2015-02-25       Impact factor: 2.352

5.  Concordance between self-report and urine drug screen data in adolescent opioid dependent clinical trial participants.

Authors:  Claire E Wilcox; Michael P Bogenschutz; Masato Nakazawa; George Woody
Journal:  Addict Behav       Date:  2013-06-13       Impact factor: 3.913

6.  Chronic opioid therapy risk reduction initiative: impact on urine drug testing rates and results.

Authors:  Judith A Turner; Kathleen Saunders; Susan M Shortreed; Suzanne E Rapp; Stephen Thielke; Linda LeResche; Kim M Riddell; Michael Von Korff
Journal:  J Gen Intern Med       Date:  2013-10-19       Impact factor: 5.128

7.  Assessing Patients' Risk for Opioid Use Disorder.

Authors:  Barbara St Marie
Journal:  AACN Adv Crit Care       Date:  2019-12-15

8.  Using cheminformatics to predict cross reactivity of "designer drugs" to their currently available immunoassays.

Authors:  Matthew D Krasowski; Sean Ekins
Journal:  J Cheminform       Date:  2014-05-10       Impact factor: 5.514

9.  Systematic evaluation of "compliance" to prescribed treatment medications and "abstinence" from psychoactive drug abuse in chemical dependence programs: data from the comprehensive analysis of reported drugs.

Authors:  Kenneth Blum; David Han; John Femino; David E Smith; Scott Saunders; Thomas Simpatico; Stephen J Schoenthaler; Marlene Oscar-Berman; Mark S Gold
Journal:  PLoS One       Date:  2014-09-23       Impact factor: 3.240

10.  Use of a data warehouse at an academic medical center for clinical pathology quality improvement, education, and research.

Authors:  Matthew D Krasowski; Andy Schriever; Gagan Mathur; John L Blau; Stephanie L Stauffer; Bradley A Ford
Journal:  J Pathol Inform       Date:  2015-07-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.